Incyte (INCY) Income towards Parent Company (2010 - 2026)
Incyte's (INCY) quarterly Income towards Parent Company came in at $585.6 million in Q2 2026, up 44.59% YoY from $405.0 million in Q2 2025, and up 93.06% on a QoQ basis from $303.3 million in Q1 2026.
Analysis
Incyte (INCY) Income towards Parent Company (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Income towards Parent Company data on file, last reported at $585.6 million in Q2 2026.
- Quarterly Income towards Parent Company rose 44.59% year-over-year to $585.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (up 85.15% YoY) and the FY2025 annual result came in at $1.3 billion, up 3844.96% from the prior year.
- Income towards Parent Company climbed to $585.6 million in Q2 2026, from $303.3 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $585.6 million in Q2 2026 to a low of -$444.6 million in Q2 2024.
- A 5-year average of $174.8 million and a median of $170.4 million in 2023 frame the typical range for Income towards Parent Company.
- The widest YoY moves for Income towards Parent Company: up 681.22% in 2024, down 318.43% in 2024.
- Tracing INCY's Income towards Parent Company over 5 years: stood at $28.5 million in 2022, then jumped by 606.51% to $201.1 million in 2023, then climbed by 0.07% to $201.2 million in 2024, then surged by 48.74% to $299.3 million in 2025, then jumped by 95.67% to $585.6 million in 2026.
- The last three Income towards Parent Company figures came in at $585.6 million (Q2 2026), $303.3 million (Q1 2026), and $299.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.21 Bn | 132.36 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.73 Bn | 58.55 Bn | 1.37 Bn |
| 4 | Moderna | 57.59 Bn | 52.46 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 40.13 Bn | 35.04 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.55 Bn | 32.24 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.60 Bn | 27.77 Bn | - |
| 9 | Insmed | 27.70 Bn | 26.54 Bn | 358.27 Mn |
| 10 | Incyte | 25.52 Bn | 20.98 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 585.61 Mn |
| Mar 31, 2026 | 303.33 Mn |
| Dec 31, 2025 | 299.28 Mn |
| Sep 30, 2025 | 424.17 Mn |
| Jun 30, 2025 | 405.00 Mn |
| Mar 31, 2025 | 158.20 Mn |
| Dec 31, 2024 | 201.21 Mn |
| Sep 30, 2024 | 106.46 Mn |
| Jun 30, 2024 | -444.60 Mn |
| Mar 31, 2024 | 169.55 Mn |
| Dec 31, 2023 | 201.08 Mn |
| Sep 30, 2023 | 171.27 Mn |
| Jun 30, 2023 | 203.55 Mn |
| Mar 31, 2023 | 21.70 Mn |
| Dec 31, 2022 | 28.46 Mn |
| Sep 30, 2022 | 112.78 Mn |
| Jun 30, 2022 | 161.43 Mn |
| Mar 31, 2022 | 37.99 Mn |
| Dec 31, 2021 | 563.86 Mn |
| Sep 30, 2021 | 181.74 Mn |